New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development

Jean-Michel Pawlotsky, MD, PhD1,2

1 National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
2 INSERM U955, Créteil, France


Abstract

The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents. Surprisingly, curing HCV infection appears to be easy with these new drugs, provided that a potent drug combination with a high barrier to resistance is used. HCV infection cure rates can be optimized by combining drugs with synergistic antiviral effects, tailoring treatment duration to the patients’ needs, and/or using ribavirin. Two HCV drugs have been approved in 2011—telaprevir and boceprevir, both first-wave, first-generation NS3-4A protease inhibitors, two others in 2013/2014—simeprevir, a second-wave, first-generation NS3-4A protease inhibitor, and sofosbuvir, a nucleotide analogue inhibitor of the viral polymerase. Numerous other drugs have reached phase II or III clinical development. From 2015 and onwards, interferon-containing regimens will disappear, replaced by interferon-free regimens yielding infection cure rates over 90%. These therapies will raise new issues, including the need for broad-scale screening and access to care.

Keywords
- hepatitis C virus
- direct-acting antivirals
- host-targeted agents
- simeprevir
- sofosbuvir

When hepatitis C virus (HCV) was discovered in the late 1980s,1 the only available treatment for what was known as chronic “non-A, non-B” hepatitis was standard interferon-alpha (IFN-α), 3 million units three times per week subcutaneously for 24 weeks. Only 6% of patients achieved a sustained virological response (SVR), i.e. a cure of HCV infection, with this regimen. The initial choice of IFN-α as a potential treatment for chronic hepatitis C was an empirical one. In 1986, Hoofnagle et al2 had written: “Alpha interferon was a natural choice as a possible therapeutic agent for chronic non-A, non-B hepatitis. This agent has a wide spectrum of antiviral activity and has been used to treat many acute and chronic viral illnesses. Alpha interferon has already been shown to inhibit replication of several human hepatitis viruses, including hepatitis A virus (in cell culture), hepatitis B virus and the hepatitis delta agent.” Prolonging IFN-α administration to 48 weeks increased the SVR rate up to 12 to 16%. Ribavirin was introduced in 19913 with the following justification: “Ribavirin is a noninterferon-inducing nucleotide analogue with a broad spectrum of activity against RNA and DNA viruses, including those from the flavivirus family.” In fact, ribavirin happened to be a very weak and transient direct inhibitor of HCV replication.4 However, when added to IFN-α, ribavirin increased the SVR rates up to 40 to 45%, through mechanisms that remain unknown. An additional 10% increase in SVR rate was achieved when standard IFN-α was replaced by pegylated IFN-α PegIFN-α, that could be administered once per week.5,6 Overall, ~ 50% of HCV-infected patients cleared infection with the combination of PegIFN-α and ribavirin, with marked differences according to the HCV genotype. This treatment regimen remained the standard-of-care until 2011 for genotype 1, and until 2013 for the other genotypes.7
The development of new models and tools used to unravel the different steps of the HCV lifecycle and an unprecedented effort of the academic field and drug industry toward the discovery and clinical development of new anti-HCV drugs led to the 2014 situation, with four approved new antiviral agents since 2011 and dozens at phase II or III clinical developmental stages. New HCV drugs split into two groups: direct-acting antivirals (DAAs) that target viral actors of the HCV lifecycle, and host-targeted agents (HTAs) that target host-cell components involved in complex interactions with viral proteins that are essential to the HCV lifecycle. The field quickly learned how to use these new compounds to optimize HCV infection cure rates. Here I describe the requirements for definitive cure of HCV, the HCV drugs currently in clinical development, and opportunities for new anti-HCV therapies in the short- to mid-term future.

Curing HCV Infection: An Easy Task

Surprisingly, curing HCV infection appeared to be an easy task, as soon as appropriate tools became available. Curing HCV replicons was easy with IFN-α, with or without ribavirin, as a result of the sustained direct antiviral effect of IFN-α in cell culture. It was more difficult in clinical practice because several factors influenced the ability of infected patients to respond to IFN-α antiviral effects. It is only recently that the prominent role of a genetic predisposition to IFN responsiveness (related to the so-called IL28B genotype) was discovered. The HCV genotype, that influences the ability of the virus to be inhibited by IFN-α and of the infected cells to cure themselves, and the severity of liver disease (extensive fibrosis or cirrhosis), that alters the latter, were both identified as important additional determinants of the SVR in IFN-α/ribavirin-based regimens. Thus, drugs with an antiviral effect not influenced by host or viral parameters, such as the DAAs or HTAs currently in development, were needed to achieve higher cure rates.

With such drugs, curing HCV infection becomes an easy task, at two conditions (Fig. 1): (1) The antiviral effectiveness of the combination of drugs used must be high enough to efficiently block virus production by infected cells. This shutdown of virus production is responsible for the first-phase HCV RNA decline, observed within the first 1 to 3 days of therapy. (2) The inhibition of virus production must be sustained on treatment. This implies that the combination of drugs has a high barrier to resistance that prevents resistant viruses from being selected and inducing a virological breakthrough in patients who are adherent to therapy. If both conditions are fulfilled, the progressive decrease of the number of infected cells is responsible for the observed second-phase decline of HCV RNA levels. It is the combined result of the natural death rate of infected cells and the rate of loss of the ability of the remaining infected cells to produce virus as their intracellular RNA degrades, which is the infected cell cure rate. The progressive loss of infected cells leads to a definitive cure of infection if the patient is still on treatment when the last infected cell is cleared or cured. Conversely, if the patient’s body still contains infected cells when treatment is stopped, infection relapses within a few days to weeks after treatment cessation.

Requirements for an HCV Cure

Antiviral Potency (First-Phase HCV RNA Decline)

As discussed by Rupp and Bartenschlager in this issue of Seminars, the HCV lifecycle offers several potential targets for DAAs and HTAs with potent antiviral activity. The lifecycle starts with receptor binding, entry into cells, and fusion. Decapsidation of viral nucleocapsids liberates free positive-strand genomic RNAs in the cell cytoplasm, where they serve, together with newly synthesized RNAs, as messenger RNAs for synthesis of the HCV polyprotein. The polyprotein is then cleaved by host cell peptidases, the NS2 autocatalytic protease and the NS3-4A serine protease to generate three structural and seven nonstructural mature viral proteins. Replication is catalyzed by the HCV RNA-dependent RNA polymerase (RdRp), and the NS5A protein plays an important regulatory role in virus replication. HCV then uses the lipoprotein production pathway to generate mature viral particles and export them.

Thus far, drugs from all classes of DAAs in clinical development, including NS3-4A protease inhibitors, nucleoside/nucleotide analogue inhibitors of HCV RdRp, nonnucleoside inhibitors of RdRp, and NS5A inhibitors, have been shown to reduce HCV replication by 3 logs or more over 3 days of administration. HTAs, such as cyclophilin A inhibitors and the microRNA-122 (miR-122) antagonist, can also reduce viral replication by more than 3 logs within a week or 2 weeks. This antiviral effectiveness is sufficient to trigger the second-phase decline. Although this has been difficult to show in vivo, because most patients become HCV RNA undetectable early...
on treatment, combining drugs from different classes yields additive to synergistic antiviral effects, as suggested by in vitro studies.15

**Barrier to Resistance (Sustainability of First-Phase HCV RNA Decline)**

Viral resistance corresponds to the selection during antiviral treatment of viral variants that bear amino acid substitutions altering the drug target, that are therefore less susceptible to the drug’s inhibitory activity.16 These drug-resistant variants pre-exist, generally as minor populations, within the patient’s quasispecies (the ensemble of all viral variant populations present in a given individual), as a result of the error-prone activity of the HCV RdRp, the large viral populations and the short half-life of the virus in peripheral blood. Drug exposure profoundly inhibits replication of the dominant, so-called wild-type, drug-sensitive viral population, and the resistant variants gradually occupy the vacant replication space.116

In vivo, viral resistance is influenced by three parameters that altogether, define the barrier to resistance of a drug or a drug class. They include (1) the genetic barrier to resistance, defined as the number of nucleotide/amino acid substitutions needed for a viral variant to acquire full resistance to the drug in question; (2) the in vivo fitness of the viral variant population, defined as its ability to survive and grow in the replicative environment; and (3) drug exposure, defined as the drug concentration achieved in vivo relative to the concentrations that must be achieved to efficiently inhibit replication of resistant variants.16

HCV DAAs in development can be split into two groups. Drugs with a low barrier to resistance include first-generation NS3-4A protease inhibitors, first-generation nonnucleoside inhibitors of HCV RdRp and first-generation NS5A inhibitors. Nucleoside/nucleotide analogues have a high barrier to resistance because the resistant viral variants they select are poorly fit and therefore do not replicate at clinically meaningful levels when they are selected. Second-generation NS3-4A protease and NS5A inhibitors have a substantially higher barrier to resistance than first-generation drugs. However, they can select fit-resistant viruses, so there is room for third-generation drugs with a truly high barrier to resistance. Finally, HTAs have a high barrier to resistance because they target conserved host-cell components involved in the HCV lifecycle, not variable viral proteins.

To ensure that the barrier to resistance of an antiviral treatment is high, drugs must be combined. Several options are available. They include (1) the combination of a drug with a high barrier to resistance (nucleoside/nucleotide analogue inhibitor of HCV RdRp or cyclophillin inhibitor), used as a “backbone,” with one (or even two) other drugs with a low barrier to resistance; (2) the combination of three first-generation drugs with a low barrier to resistance (NS3-4A protease inhibitor, NS5A inhibitor, and nonnucleoside inhibitor of HCV RdRp). Two such drugs (NS3-4A protease inhibitor and NS5A inhibitor) may be sufficient in easy-to-cure patients, such as those infected with HCV genotype 1b with a CC IL28B genotype; (3) the combination of two drugs including at least one second-generation NS3-4A protease or NS5A inhibitor. These approaches have been assessed in phase II and III clinical trials and were all shown to ensure a high barrier to resistance in treatment-adherent patients.

**Clearance of Infected Cells (Second-Phase Decline)**

The loss/cure of infected cells upon antiviral therapy is under the control of multiple parameters, some of which can be modified to optimize treatment responses. The factors that cannot be modified include the patient’s genetic background, disease characteristics such as extensive fibrosis or cirrhosis, and the HCV genotype. The factors that can be modulated include the antiviral effectiveness of the drug combination, treatment duration, and the use of ribavirin.

**Factors That Cannot Be Modified**

The IL28B genotype is a strong predictor of IFN responsiveness—the ability of IFN-α to significantly reduce HCV replication.9 In contrast, host genetics do not influence the first-phase decline on DAA-based therapy. However, the second-phase HCV RNA decline is influenced by the IL28B genotype in patients receiving IFN-free regimens. Indeed, the second-phase slope was shown to be significantly steeper in CC than in CT or TT patients.17,18 This means that higher SVR rates can be obtained with a given duration in CC patients, or alternatively, that longer treatment is needed in non-CC patients to achieve the same SVR rate with a given combination regimen.18 This observation also indicates that the ability of infected cells to be cured when virus production is blocked is genetically determined, and probably related to intracellular IFN responses, suggesting a key role of innate immunity in HCV clearance on therapy.

Extensive fibrosis and cirrhosis are associated with lower SVR rates on both IFN-containing and IFN-free combination regimens.19,20 This is due to a slower second-phase HCV RNA decline in cirrhotic than in noncirrhotic patients. The molecular mechanisms underlying the slower infected cell clearance in cirrhotic patients are unknown. It does not appear to be related to different drug exposures in cirrhotics because the first-phase response is identical in cirrhotic and noncirrhotic patients. Differences in the cirrhotic liver microenvironment might be responsible for subtle differences in the mechanisms of HCV clearance activated in infected cells on efficient antiviral therapy.

The HCV genotype was recently shown to influence the second-phase HCV RNA decline in patients receiving IFN-free regimens, through unknown mechanisms. Thus, with a given combination regimen, longer treatment is needed in patients infected with HCV genotypes that have a slower second-phase decline.19–21 Schematically, HCV genotypes can be classified as follows in order of slowing second-phase: genotype 2, genotype 1b, genotype 1a, and genotype 3. For this reason, genotype 3 has become the most difficult-to-cure HCV genotype. Not enough data are available for genotypes 4, 5, and 6.

**Factors That Can Be Modified**

The loss of infected cells (second-phase slope) was shown to be significantly related to the antiviral effectiveness of the
drug regimen used (first-phase slope).22 Thus, more potent antiviral drug combinations are associated with a more rapid loss of infected cells, even though the latter is not due to the direct antiviral effect of the drugs. It is therefore important to use potent, synergistic combinations of antiviral drugs to optimize both first-phase and second-phase HCV RNA declines.

Treatment duration is a key parameter that can be easily optimized to increase the SVR rates. Stopping treatment too early, that is before the last infected cell has been cleared or cured, results in reinfection of adjacent, then distant liver cells, and ultimately, in a virological relapse. In contrast, stopping therapy at any time after the last cell has been eliminated is associated with a definitive cure of infection. Thus, patients with a slow second-phase decline, such as patients with an unfavorable IL28B genotype, cirrhotics, patients infected with HCV genotype 3, etc., need longer therapy than those with a sharp one, regardless of the treatment regimen. As a result, one size does not fit all, and different subgroups of patients receiving a given drug combination may need different treatment durations to achieve an SVR, as recently shown with the combination of sofosbuvir and ribavirin in different groups of patients infected with HCV genotypes 1, 2, and 3.19-21 This will also be true with more potent drug combinations that need shorter treatment durations. Thus, treatment duration with a given regimen must either be adapted to each subgroup of patients, or to simplify, tailored to the group that needs the longest treatment to avoid too many failures in the more difficult-to-cure patients. Current clinical development strategies aim to identify, for each treatment regimen, the shortest duration with the highest global SVR rate. This approach may be dangerous, as a treatment strategy validated in a phase III clinical trial may happen to be too short when applied to more difficult-to-cure real-life patients. The current race for shorter therapy may thus lead to undertreat a substantial proportion of patients in clinical practice.

Ribavirin accelerates the second-slope of viral decline in a dose-dependent manner in patients in whom virus production is efficiently blocked by IFN-containing or IFN-free drug combinations, through mechanisms that remain debated.4,23 Thus, ribavirin remains a useful tool to either reduce treatment duration or improve SVR rates with a given duration, as less time will be needed for all infected cells to be cleared/cured. Because ribavirin is cheap and relatively well tolerated when it is not combined with IFN-α, it remains a very useful tool to fine tune anti-HCV treatment regimens and optimize their results.

New Approved HCV Drugs or in Clinical Development

Approved Drugs
Pegylated IFN-α2a and IFN-α2b and ribavirin are still available for triple or quadruple IFN-containing regimens with new HCV drugs, as discussed by Aronsnoh and Jensen in this issue. Telaprevir and boceprevir are first-wave, first-generation NS3-4A protease inhibitors that were approved in 2011 for use in combination with PegIFN-α and ribavirin. They are specific for genotype 1 and have a low barrier to resistance. Their use was associated with frequent side effects, including cutaneous complications, anemia, gastrointestinal disorders and renal toxicity for telaprevir; and anemia, dysgeusia, and renal toxicity for boceprevir, as well as with frequent drug–drug interactions due to their metabolism by cytochrome P450 CYP34A that they inhibit.24-29 For these reasons, these drugs will no longer be used when better tolerated compounds are available.

Two new HCV DAAs have been approved in the United States in December 2013, in Europe in the first half of 2014 simeprevir and sofosbuvir. Simeprevir is a second-wave, first-generation NS3-4A protease inhibitor. Its genotypic coverage is broader than that of the first-wave drugs, including at least genotypes 1, 2, and 4; however, simeprevir is inactive against HCV genotype 3. Simeprevir has a low barrier to resistance, with extensive cross resistance with telaprevir and boceprevir and the other first-generation NS3-4A protease inhibitors. In addition, simeprevir preferentially selects resistant variants bearing the Q80K substitution in the NS3 protease sequence. The presence of detectable levels of these variants at baseline has been associated with failures of simeprevir-containing regimens.30-32 Phase II and III clinical trials have shown an excellent tolerance profile for this compound.30-32 Simeprevir only modestly inhibits CYP34A.

Sofosbuvir is a first-generation uridine nucleotide analogue inhibitor of HCV RdRp, which is phosphorylated into its triphosphate form and incorporated into the RNA chain in formation, thus acting as a chain terminator. Sofosbuvir has pangenotypic antiviral activity, confirmed in vivo against genotypes 1 to 6.19,20,33 In vitro, sofosbuvir selects variants with an S282T substitution in the RdRp sequence.33 However, these variants have considerably impaired replication capacity, both in vitro and in vivo. As a result, they have never been associated with virological breakthroughs on treatment, and were exceptionally found in patients who relapsed after treatment withdrawal.19,20 Thus, sofosbuvir has a high barrier to resistance. Sofosbuvir was well tolerated in phase II and III clinical trials that included several thousand patients.19,20 It is not metabolized by CYP450. Thus, sofosbuvir has few drug–drug interactions, except with potent P-glycoprotein and/or breast cancer resistance protein inducers.

Drugs in Clinical Development
NS3-4A Protease Inhibitors
NS3-4A protease inhibitors in development include second-wave, first-generation drugs that share simeprevir’s properties, including broad genotypic coverage that excludes genotype 3 and a low barrier to resistance with cross-resistance with other first-generation inhibitors. The most frequently selected substitutions conferring resistance to first-generation NS3-4A protease inhibitors have been described at amino acid positions V36, T54, R155, A156, D168, and V170.19 The Q80K substitution is preferentially selected by simeprevir. Drug–drug interactions have been reported for some of them.

Compounds in phase II or III clinical development include faldaprevir (Boehringer-Ingelheim, Ingelheim, Germany), likely approved in 2014 in combination with PegIFN-α and ribavirin; asunaprevir (Bristol-Myers Squibb, New York, NY),
possibly approved in 2014 or 2015; ABT-450 (Abbvie, North Chicago, IL) boosted by ritonavir, likely approved in 2014 or 2015 as part of the first all-oral, IFN-free combination for HCV genotype 1 infection; vedرهپرویر (Gilead, Foster City, CA); IDX-320 (Idenix Pharmaceuticals, Cambridge, MA); sovапرویر (Achillion Pharmaceuticals, New Haven, CT), on clinical hold due to elevated alanine aminotransferase levels in a drug–drug interaction study with atazanavir; danopرویر (Hoffmann-La Roche, Basel, Switzerland), boosted by ritonavir; vanipرویر (Merck, White House Station, NJ), that will be developed in Japan only (►Fig. 2). Second-generation NS3-4A protease inhibitors have pan genotypic antiviral activity, including genotype 3, and a higher barrier to resistance than first-generation drugs. However, resistant HCV variants can be selected by these compounds. They include MK-5172 (Merck), possibly approved in 2015 or 2016, and ACH-2684 (Achillion) (►Fig. 2).

Nucleoside/Nucleotide Analogue Inhibitors of HCV RdRp

Few nucleoside/nucleotide analogues remain at the clinical developmental stage after several programs were halted due to serious, sometimes fatal toxicity. VX-135 (Vertex Pharmaceuticals, Cambridge, MA) is a pyrimidine analogue on partial clinical hold following the observation of reversible elevated liver enzymes in patients receiving a high dose of the drug. Mericitabine (Roche) is a modestly potent cytidine nucleoside analogue still in development (►Fig. 2).

Nonnucleoside Inhibitors of HCV RdRp

Nonnucleoside inhibitors of HCV RdRp bind to one of four allosteric sites on the polymerase, thereby altering its catalytic function. Two sites are located in the “thumb” domain and two in the “palm” domain. Nonnucleoside inhibitors of HCV RdRp are generally active against HCV genotype 1 only and they have a low barrier to resistance, with extensive cross resistance between drugs targeting the same allosteric site and possible cross resistance between drugs targeting different sites. Thumb-1 inhibitors include deleобувир (Boehringer-Ingelheim), the development of which has been stopped in January 2014, BMS-791325 (Bristol-Myers Squibb), and TMC47055 (Janssen). The two latter belong to triple-combination regimens that will seek approval in 2015 or 2016. Thumb-2 inhibitors include filibuvир (Pfizer, New York, NY), the development of which has been stopped, lомибувир (Vertex) and GS-9669 (Gilead). Palm-1 inhibitors include setробувир (Roche), and ABT-333 (Abbvie), which will likely be approved in 2014 or 2015 in combination with other DAAs, and ABT-072 (Abbvie). Palm-2 inhibitors include tegобувир (Gilead), the development of which has been stopped (►Fig. 2).

NS5A Inhibitors

NS5A inhibitors bind to domain 1 of the NS5A protein and block both replication and viral assembly and release. Due to their double mode of action, NS5A inhibitors induce a rapid and profound HCV RNA decline upon administration. First-
generation NS5A inhibitors are active against genotypes 1 and 4. Some of them, but not all, are also active against genotypes 2 and/or 3. Their activity against genotypes 5 and 6 has not been tested in most cases. They have a low barrier to resistance, especially for genotype 1a and for genotype 3 for those active against this genotype. The most frequently selected substitutions are at positions M28, Q/A30, L31, and Y93 in the NS5A sequence. Variants bearing these substitutions persist after treatment failure in most cases, raising the issue of retreatment with a combination that includes an NS5A inhibitor.

First-generation NS5A inhibitors in development include daclatasvir (Bristol-Myers Squibb), likely approved in 2014 or 2015 for use in IFN-containing and IFN-free combinations; ledipasvir (Gilead), available as a fixed-dose combination (one pill) with sofosbuvir, likely approved in 2015; ABT-267 (Abbvie), likely approved in 2014 or 2015 in combination with ritonavir-boosted ABT-450 and ABT-333; PPI-668 (Presidio Pharmaceuticals, San Francisco, CA); ACH-2928 (Achillion); GS2336805 (GlaxoSmithKline); BMS824393 (Bristol-Myers Squibb); and samatasvir (Idenix) (Fig. 2). All of them are currently being tested as part of double- or triple-combination IFN-free regimens.

Second-generation NS5A inhibitors have reached clinical development. They have pangenotypic activity and their barrier to resistance has been improved. However, they have been shown to select amino acid substitutions that confer resistance to first-generation compounds. They include MK-8742 (Merck), likely approved in 2015 or 2016 in combination with MK-5172; ACH-3102 (Achillion); and GS-5816 (Gilead), which may ultimately replace ledipasvir in the fixed-dose combination with sofosbuvir (Fig. 2).

**Host-Targeted Agents**

Two classes of host-targeted agents have reached clinical development. They include specific inhibitors of cyclophilin A peptidyl-prolyl cis/trans isomerase activity and antagonists of miR-122. These compounds have pangenotypic activity, a high barrier to resistance and they are well tolerated in the absence of IFN-α coadministration. Cyclophilin inhibitors in clinical development include alisporivir (Novartis, Basel, Switzerland) and SCY-635 (Scynexis, Inc., Durham, NC) (Fig. 2). Alisporivir was put on clinical hold due to a fatal case of acute pancreatitis that occurred in combination with PegIFN-α and ribavirin. It is now back in development in all-oral, IFN-free combination regimens. The miR-122 antagonist miraviren (Santaris Pharma, Copenhagen, Denmark) is available in an injectable form. Two weeks of administration reduced HCV replication by several logs. However, concerns have been raised as to the long-term hepatic effects of inhibiting miR-122 and the risk of steatohepatitis, fibrosis, and hepatocellular carcinoma.

**HCV Treatment Strategies**

**Until 2014**

For the past 15 years, the treatment of chronic hepatitis C has been based on the use of PegIFN-α and ribavirin. In 2011, telaprevir and boceprevir were approved in combination with PegIFN-α and ribavirin for patients infected with HCV genotype 1. This triple combination improved the SVR rates by 15 to 20% compared with PegIFN-α and ribavirin alone. Easy-to-cure patients—patients with mild liver disease—were those with the highest SVR rates. However, frequent and often serious side effects were observed with this regimen, especially in patients with advanced liver disease who marginally benefited from the addition of the protease inhibitor. Because of the complexity of these therapies and of the arrival of new, more efficient, and better-tolerated treatments, most patients who could wait for new treatment regimens were not treated in 2013 in the United States and Europe.

**2014–2015**

Two HCV DAAs were approved in December 2013 in the United States and in the first half of 2014 in Europe: simeprevir and sofosbuvir. Four treatment options are available in 2014 for the treatment of chronic hepatitis C, including IFN-containing and IFN-free regimens. IFN-containing options include the triple combination of PegIFN-α, ribavirin, and simeprevir 24 to 48 weeks for patients infected with HCV genotype 1 (excluding those infected with subtype 1a with a detectable Q80K substitution in the NS3-4A protease sequence at baseline), that yields SVR rates of the order of 80%; and the triple combination of PegIFN-α, ribavirin, and sofosbuvir for 12 weeks for patients infected with HCV genotypes 1 to 6 that yields SVR rates of the order of 90% or more. IFN-free options include the combination of sofosbuvir and ribavirin 12 weeks for patients infected with HCV genotype 2, that yields SVR rates over 95% (except in patients with cirrhosis who may need slightly longer treatment), the combination of sofosbuvir and ribavirin 24 weeks for patients infected with HCV genotype 3, that yields SVR rates over 95% in noncirrhotic patients, and up to 60% in patients with cirrhosis. The combination of sofosbuvir and simeprevir, with or without ribavirin, can also be used in patients infected with HCV genotypes 1 and 4, based on results of a small-scale phase II trial including null responders to a prior course of treatment with extensive fibrosis or cirrhosis showing SVR rates of 95 to 100%.

**2015 and Onward**

IFN-containing regimens will progressively disappear, replaced by all-oral IFN-free regimens. Phase II trials of different drug combinations have shown SVR rates of the order of more than 90%. The recent release of preliminary results from phase III trials confirmed that most, if not all patients can achieve an SVR with these regimens, at least in clinical trials. The combination of the second-wave, first-generation protease inhibitor ABT-450 boosted by ritonavir, the NS5A inhibitor ABT-267, and the nonnucleoside inhibitor of HCV RdRp ABT-333 plus ribavirin for 12 weeks yielded SVR rates of 95% in subtype 1a and 98% in subtype 1b treatment-naive patients, and 96% in subtype 1a and 97% in subtype 1b treatment-experienced patients (SAPPHIRE-1 and SAPPHIRE-2 phase III trials). In the ION-1, ION-2, and ION-3 phase III...
trials with the fixed-dose combination of sofosbuvir and ledipasvir in patients infected with HCV genotype 1, the SVR rates were 97.7% and 97.2% with or without ribavirin, respectively, after 12 weeks of therapy in treatment-naïve patients (including 16% with cirrhosis); 94.0%, 93.1%, and 95.4% without ribavirin for 8 weeks, with ribavirin for 8 weeks and without ribavirin for 12 weeks in treatment-naïve patients, respectively; 93.6% and 96.4% with or without ribavirin, respectively, after 12 weeks, and 99.1% and 99.1% with or without ribavirin, respectively, after 24 weeks of therapy in treatment-experienced patients (including 20% with cirrhosis). Other phase III trials are ongoing with the same and other drug combinations.

Conclusion

Curing HCV infection is an easy task, provided that appropriate tools—potent drug combinations with a high barrier to resistance—are used. This has become possible with the discovery of several new HCV DAAs and HTAs that have reached phase II and phase III clinical development. SVR rates as high as 95% or more have been reported in phase III trials with the dozens of ongoing studies with different treatment regimens in various populations of HCV-infected patients, indicate that the IFN era is getting to its end in HCV therapy. New all-oral, IFN-free strategies, described in detail in various articles in this issue, will take over. However, they will raise new issues that will need to be tackled, including the need for broad-scale screening, access to care, and the high costs associated with the drugs.

Conflict of Interest Disclosure

The author has received research grants from Gilead Sciences. He has served as an advisor for Abbott, Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.

References

38 Pawlotsky JM, Sarin SK, Foster GR, et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology 2012;56:309A–310A
41 Abbvie. Abbvie demonstrates 96 percent SVR-12 in its phase III study of treatment experienced patients with genotype 1 hepatitis C. Available at: http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in-its-Phase-III-Study-of-Treatment-Experienced-Patients-with-Genotype-1-Hepatitis-C